The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Quick Searches
Selecting one or more of the options below will update the content below.
- Clinical TrialCanada-Wide
What is this Study about?
This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease.
Eligibility Criteria
50 years or older, with mild to moderate Alzheimer’s Disease
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
Eligibility Criteria
- Age 50-85 years old
- Diagnosis of early AD
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
Multi-center, Double-Blind, Placebo-Controlled Phase 1/2 Trial to Assess the Safety and Tolerability of WVE-3972-01 Administered Intrathecally to Patients with Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).
Eligibility Criteria
- 18 Years to 80 Years
- Participants must have a documented mutation (GGGGCC [G4C2] repeat expansion) in the first intronic region of the C9orf72 gene and be diagnosed with ALS or FTD.
- Have a designated study partner
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period.
Eligibility Criteria
- 50 Years to 80 Years
- Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD
- Have a designated study partner
Recruitment End Date
- Clinical TrialBritish Columbia, Nova Scotia, Ontario, Quebec
What is this Study about?
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE).
Eligibility Criteria
- 55 Years to 85 Years
- MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type
- Have a designated study partner
Recruitment End Date
- Clinical TrialBritish Columbia, Nova Scotia, Ontario, Quebec
What is this Study about?
A Phase 3 randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
Eligibility Criteria
- 55 Years to 85 Years
- MCI (mild cognitive impairment) or mild dementia of the Alzheimer's type
- Have a designated study partner
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
Eligibility Criteria
- 55 Years to 80 Years
- Early Alzheimer's disease (AD)
- Have a designated study partner
Recruitment End Date
- Clinical TrialOntario
What is this Study about?
This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.
Eligibility Criteria
- 50-85 years old
- Diagnosis of early Alzheimer's Disease
Recruitment End Date
- Clinical TrialBritish Columbia, Nova Scotia & Ontario
What is this Study about?
The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 76-week, repeat-dose oral administration in participants with mild-to-moderate AD.
Eligibility Criteria
- 50-87 years of age
- Diagnosis of mild-to-moderate Alzheimer's Disease
- You do not smoke or use nicotine product
Recruitment End Date
Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: [email protected]
Charity registration number: 11878 4925 RR0001
Follow us: